首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis and structure-activity relationships of novel arylalkyl 4-benzyl piperazine derivatives as sigma site selective ligands.
【24h】

Synthesis and structure-activity relationships of novel arylalkyl 4-benzyl piperazine derivatives as sigma site selective ligands.

机译:新型芳烷基4-苄基哌嗪衍生物作为sigma位点选择性配体的合成与构效关系。

获取原文
获取原文并翻译 | 示例
           

摘要

Continuing our previous work that established that some chromones substituted by an aryl alkyl piperazino alkyl side chain are potent and selective sigma ligands and could be interesting in the treatment of psychosis, we synthesized 60 new compounds, replacing the chromone moiety by various cyclic systems. Many derivatives bind to the sigma sites in the nanomolar range and are generally selective in comparison with 5HT(1A) and the D(2) receptors. One of the most potent ligands of these series, 1-(2-naphthyl methyl)-4-benzyl piperazine 29, has been studied in various pharmacological tests. Although it doesn't have potential in the treatment of psychosis, the results we obtained confirm the data which indicates that such derivatives could be interesting in the treatment of inflammatory diseases.
机译:继续我们先前的工作,即确定被芳基烷基哌嗪子烷基侧链取代的某些色酮是有效的选择性σ配体,在精神病的治疗中可能是令人感兴趣的,我们合成了60种新化合物,用各种环状系统取代了色酮部分。许多衍生物与纳摩尔范围内的sigma位点结合,与5HT(1A)和D(2)受体相比通常具有选择性。这些系列中最有效的配体之一是1-(2-萘基甲基)-4-苄基哌嗪29,已在各种药理学试验中得到了研究。尽管它在治疗精神病方面没有潜力,但我们获得的结果证实了数据,表明这些衍生物可能在炎性疾病的治疗中令人感兴趣。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号